Function Health Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Function Health and How Does Its Model Work?

Function Health positions itself as a lab-driven longevity company. Members pay roughly $499 per year for access to a broad panel of more than 100 blood and urine biomarkers, an interpretive dashboard, and a telehealth layer that can result in prescriptions for medications including thyroid drugs, hormones, and metabolic agents.

The subscription-plus-Rx structure is not unique. Companies such as Hims and Hers, Ro, and LifeMD operate under similar frameworks. What distinguishes Function Health's marketing is its emphasis on "proactive" and "data-driven" medicine rather than symptom-driven care.

How the Telehealth Prescribing Layer Works

Telehealth prescribing in the United States is governed by the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which requires a valid patient-practitioner relationship before a controlled substance can be prescribed online [1]. For non-controlled medications, state medical practice acts define the standard. Function Health's affiliated clinicians must hold active medical licenses in the states where they treat patients.

The FDA regulates drug labeling and compounding under the Federal Food, Drug, and Cosmetic Act [2]. When a telehealth platform dispenses compounded hormones or GLP-1 analogs, those products must comply with Section 503A or 503B compounding rules. The FDA has issued multiple warning letters to 503A pharmacies for quality failures since 2022, a pattern relevant to any telehealth brand sourcing compounded products [3].

What "Prescribing Data" Means in This Context

"Prescribing data" refers to the aggregate record of which drugs a platform's clinicians order, at what doses, for which diagnoses, and with what measured outcomes. Genuine prescribing data would appear as a published registry, a payer claims analysis, or a prospective cohort study. None of those exist for Function Health in indexed literature as of January 2025 [4].

Is Function Health Legit? Regulatory and Credentialing Signals

"Legit" in the context of telehealth has a precise meaning: licensed prescribers, verified pharmacy partners, transparent pricing, and compliance with federal and state law.

Medical Board Licensure

Every physician or nurse practitioner associated with a telehealth platform must hold an active, unrestricted license in the patient's state. The Federation of State Medical Boards maintains a public lookup tool at docinfo.org, and individual state boards publish licensure status online [5]. Patients using Function Health can verify their assigned clinician's license number through their state board website before accepting any prescription.

The American Telemedicine Association's 2023 practice guidelines state that "clinicians providing telehealth services must be licensed in the state where the patient is located at the time of the encounter" [6]. Function Health's model depends on this compliance. No public enforcement action by a state medical board against Function Health's affiliated clinicians was identified in the sources reviewed for this article.

LegitScript Status

LegitScript is an independent certification body that evaluates online pharmacies and telehealth platforms for legal compliance, prescription validity, and pharmacy accreditation [7]. A LegitScript "certified" seal indicates the platform has undergone active vetting. Function Health does not appear in LegitScript's certified merchant database as of January 2025. Absence of certification is not proof of fraud, but it removes one layer of independent verification that consumers and payers use to assess platform legitimacy.

BBB Standing and Complaint Patterns

The Better Business Bureau profile for Function Health shows no BBB accreditation as of January 2025. The complaint volume publicly visible on BBB is low relative to the platform's stated membership size, which may reflect the company's relative youth or underreporting. Complaint categories in the telehealth sector nationally tend to cluster around billing disputes, prescription delays, and difficulty canceling subscriptions, according to the FTC's 2023 review of negative-option subscription practices [8].

What Outcomes Data Exists for Subscription Lab Panels?

Function Health's core product is the comprehensive lab panel, not a specific drug. Evaluating that product requires asking whether broad periodic biomarker testing in asymptomatic adults improves clinical outcomes.

Evidence From Preventive Screening Research

The U.S. Preventive Services Task Force evaluates preventive interventions using a formal evidence framework. For many of the biomarkers Function Health tests, the USPSTF has specific evidence-based recommendations [9]. Lipid screening for adults, thyroid-stimulating hormone testing, hemoglobin A1c for prediabetes screening, and ferritin panels each have defined clinical indications and intervals.

Testing outside those indications in low-risk populations generates false positives. A 2019 analysis in JAMA Internal Medicine estimated that annual comprehensive metabolic panels in healthy adults produce a false-positive rate of approximately 26% for at least one result, driving unnecessary follow-up testing and patient anxiety [10]. Function Health's 100-plus biomarker panel would be expected to generate a similar or higher false-positive burden per panel.

The "Longevity" Outcome Gap

No randomized controlled trial has demonstrated that comprehensive annual biomarker surveillance in healthy adults reduces all-cause mortality, cardiovascular events, or cancer incidence in the general population. The Danish General Suburban Population Study (N=59,616) found that general health checks did not reduce cardiovascular mortality at 10 years [11]. The USPSTF found insufficient evidence to recommend routine annual physical examinations with comprehensive lab work for asymptomatic adults aged 18 to 39 [12].

Function Health's marketing implies a longevity benefit. That benefit has not been established in prospective trials for the specific testing cadence and biomarker set the company offers.

Hormone and Metabolic Panels: Where Selective Testing Has Evidence

Targeted testing does carry outcome benefit in defined populations. The American Association of Clinical Endocrinology recommends TSH screening every five years in adults over 35, with earlier testing in symptomatic patients [13]. The American Diabetes Association's 2024 Standards of Care recommend HbA1c or fasting glucose screening every three years in adults with overweight or obesity and one additional risk factor [14]. Testosterone measurement is supported in men with symptoms consistent with hypogonadism, per the Endocrine Society's 2018 clinical practice guideline [15].

Function Health tests all of these markers. The clinical value depends entirely on whether the ordering clinician interprets results within guideline-supported thresholds and refers or treats appropriately, not on the breadth of the panel itself.

Prescribing Transparency: What Function Health Publishes (and Does Not)

Prescribing transparency means publicly reporting what drugs are prescribed, in what proportions, at what doses, and with what patient outcomes. Mature telehealth companies and traditional health systems increasingly publish this data. Function Health has not.

What Transparent Prescribing Looks Like

The FDA's Sentinel System and CMS's Open Payments database are federal examples of prescribing transparency infrastructure [16]. Academic telehealth studies, such as the 2022 analysis of GLP-1 prescribing patterns across 14 telehealth platforms published in Diabetes Care, provide a model for how platforms can report aggregate outcomes without exposing individual patient data [17].

Patients asking whether semaglutide or tirzepatide prescribed through Function Health produces weight loss comparable to clinical trial results deserve a data-driven answer. In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [18]. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [19]. A platform serious about outcomes would track whether its prescribing achieves similar results.

Compounded GLP-1 Products and FDA Enforcement

From 2022 through 2024, the FDA placed semaglutide and tirzepatide on its drug shortage list, which permitted 503A and 503B pharmacies to compound those molecules. The FDA issued a shortage determination update in early 2025 removing tirzepatide from shortage status, triggering enforcement implications for platforms still dispensing compounded tirzepatide [20]. Function Health, like other telehealth platforms that may dispense compounded GLP-1 products, must adapt prescribing to FDA shortage status in real time. Patients should ask their Function Health clinician specifically whether they are receiving FDA-approved branded product (Ozempic, Wegovy, Mounjaro, Zepbound) or a compounded version, and from which pharmacy.

Hormone Prescribing Without Published Outcome Signals

Function Health's telehealth layer appears to include testosterone replacement therapy and thyroid hormone prescribing. The Endocrine Society's 2018 testosterone therapy guideline cautions against prescribing in men with a total testosterone above 264 ng/dL without confirmed symptoms of hypogonadism [15]. The guideline also requires two morning testosterone measurements on separate days before initiating therapy. Whether Function Health's clinical workflow enforces these standards is not publicly documented.

For thyroid hormone, the American Thyroid Association's 2014 guidelines recommend levothyroxine treatment when TSH exceeds 10 mIU/L in overt hypothyroidism, with individualized decisions for subclinical hypothyroidism between 4.5 and 10 mIU/L [21]. Prescribing levothyroxine to patients with TSH in the normal range on the basis of self-reported fatigue alone is outside guideline support and carries arrhythmia risk.

Function Health Complaints: Common Categories

Reported complaints about Function Health from publicly visible sources fall into several categories worth examining separately.

Billing and Subscription Issues

The FTC's 2023 negative-option rule enforcement actions targeted subscription services that made cancellation difficult or that charged members after cancellation requests [8]. Telehealth subscriptions, including Function Health's annual membership, fall within this regulatory scope. Consumers who attempt to cancel mid-year should document all cancellation requests with timestamps.

Prescription Fulfillment Delays

Telehealth platforms that use compounding pharmacies face longer fulfillment timelines than those with direct retail pharmacy relationships. Compounding pharmacies are not required to maintain the same inventory standards as FDA-approved drug manufacturers. Delays of two to four weeks for compounded GLP-1 or hormone products have been reported across the telehealth sector broadly [22].

Interpretation Accuracy

A comprehensive panel returning 100-plus values will produce out-of-range flags. The clinical significance of mildly abnormal results depends on clinical context that an algorithm alone cannot reliably supply. Patients who receive an out-of-range flag without a synchronous clinical conversation may experience unnecessary anxiety or seek unnecessary follow-up care. The 2019 JAMA Internal Medicine analysis cited above estimated that 26% of healthy adults will receive at least one false-positive result from a comprehensive metabolic panel [10].

Data Privacy

Function Health collects sensitive health data. The HIPAA Security Rule requires covered entities and business associates to implement administrative, physical, and technical safeguards for protected health information [23]. Patients should confirm that Function Health's business associate agreements with its lab partners and pharmacy vendors meet HIPAA standards, and should read the privacy policy for language about de-identified data sharing or sale.

How to Evaluate Any Telehealth Prescribing Platform

The FDA, FTC, and state medical boards have each published guidance for patients evaluating online prescription services.

A Five-Point Verification Checklist

1. Confirm the prescriber's medical license is active and unrestricted in your state using your state medical board's public lookup [5].
2. Check whether the dispensing pharmacy holds state pharmacy board licensure and NABP VIPPS accreditation [24].
3. Ask whether the medication you are being prescribed is FDA-approved and brand-name, or compounded, and from which specific pharmacy.
4. Verify that the platform does not appear on the FDA's list of fraudulent online pharmacies [25].
5. Review the subscription cancellation policy in writing before entering payment information, consistent with FTC guidance [8].

Function Health can be evaluated against each of these criteria by any prospective member. The criteria apply equally to all telehealth platforms, not only to Function Health.

What Would Strengthen Confidence in Function Health's Outcomes Claims?

Four concrete steps would meaningfully improve the evidentiary standing of Function Health's longevity and prescribing claims.

Publishing a prospective cohort study tracking clinical outcomes (cardiovascular events, diabetes incidence, cancer detection rate, all-cause mortality) in members versus a matched comparison group over at least three years would provide a signal no competitor currently offers. Obtaining LegitScript certification would add independent third-party vetting. Disclosing aggregate prescribing data, including the proportion of members prescribed each drug class and the average lab-value changes at six and twelve months, would allow independent evaluation. Enrolling in an IRB-approved clinical registry would allow outcomes data to be submitted to ClinicalTrials.gov and eventually peer-reviewed.

None of these steps have been announced as of January 2025.